The most consequential MDMA developments right now are not in the clinic. They are in the patent office. Two facts explain why. MDMA the molecule cannot be patented, since it was first synthesized in 1912 and its original patent expired generations ago. And the defining barrier to MDMA-assisted therapy is the marathon dosing session, roughly eight hours that ties up a clinic room and two trained therapists for most of a day. Put those together and the commercial strategy in MDMA becomes clear: if you cannot own MDMA, and MDMA’s session is too long to scale, then own a shorter molecule. The result is a quiet race to patent engineered MDMA-class analogues with a truncated duration of action.
The unpatentable-molecule problem
The prize is real. Spravato, the esketamine nasal spray, remains the only approved psychedelic-adjacent psychiatric drug, and it generated more than 780 million dollars in the first three quarters of 2024, which is the number that keeps pharmaceutical interest alive in this space. But that revenue rests on a patentable molecule and formulation. MDMA offers no such protection on its own. The routes to a defensible commercial position are therefore narrow: proprietary formulations, which is the path the developer formerly known as MAPS took when it quietly filed MDMA formulation patents around 2022 in a notable reversal of its long-advertised no-patent stance, or genuinely novel analogues, new chemical entities in the MDMA class that can be owned outright.
Why short-acting is the design goal
The analogue strategy becomes far more interesting when the design objective is a shorter duration. An MDMA-class compound that preserves the entactogenic, trust-and-openness effect thought to do the therapeutic work, while compressing the experience into something that fits a normal appointment, would attack the single biggest operational constraint on the treatment. This is the same duration-engineering logic the desk has tracked across the field: Cybin’s deuterated psilocin, designed to shorten the psilocybin trip, and DMT, whose native brevity is its entire clinical pitch. Short-acting MDMA analogues are the MDMA expression of that strategy, and they carry a second advantage the originals lack. A novel analogue is patentable in a way MDMA is not, so a shorter molecule solves the commercial problem and the logistical problem in one move.
The clearest documented example is Mydecine Innovations Group’s MYCO-006 family, a set of MDMA analogs the company explicitly designed for a shorter half-life than MDMA and filed for patent protection under the title novel short-acting psychoactive compounds of the MDMA class. Whatever becomes of any single company, that filing is the template: engineer a shorter MDMA, patent the new molecule, and position it for a therapy model that fits how clinics actually run.
Why the timing makes sense
The FDA’s rejection of the MDMA application in August 2024, and its request for another Phase 3 trial, left the regulatory path for MDMA itself slow and uncertain. Counterintuitively, that strengthens the case for analogues rather than weakening it. For a commercial actor, an uncertain path for an unpatentable molecule is the least attractive position imaginable. A proprietary, patentable, session-shortening analogue lets a developer own the compound, control its regulatory filing, and design out the logistical barrier from the start. The rejection pushed the smart commercial money further toward the analogue strategy and away from the original molecule.
IP as the leading indicator
Almost no one covers behavioral-health patent filings as news, but in psychedelics, intellectual property is strategy made visible. Because the foundational molecules, MDMA, psilocybin, and DMT, cannot be patented, the commercial contest is fought over analogues, formulations, and methods of use, and those surface first as patent filings, frequently years before any clinical or regulatory milestone. Watching the filings is watching the strategy form in real time. The cluster of short-acting MDMA-analogue applications is a clear instance: it identifies who is betting that the future of MDMA therapy is a shorter, owned molecule rather than the original compound.
The caveats
Several cautions are essential. A patent filing is a statement of intent, not a product, and an early-stage or unexamined application is the weakest form of that statement; most filings never become approved medicines. The short-acting space is also not open territory, as the existing MYCO-006 filings and the formulation patents already on file mean any new entrant is moving into a field with incumbent intellectual property and real freedom-to-operate questions, and at least one MDMA formulation claim has already been found obvious over a competitor’s earlier filing. The core scientific premise is itself unproven: it is not established that MDMA’s duration can be truncated while preserving the therapeutic effect, since the length of the experience may be coupled to the benefit, the same open question that hangs over short-acting psilocybin and DMT. And a novel analogue faces the full, slow development path of a new chemical entity, so patentable does not mean faster to market.
The frame
MDMA therapy’s future is being shaped less by the molecule’s stalled regulatory path than by the contest to own a better version of it. Because MDMA cannot be patented and its session is too long, the commercial bet is on short-acting, proprietary analogues that fit a clinic and can be defended as intellectual property. The patent filings are the leading indicator of that bet, visible now, well ahead of any trial result. For a field in which IP is strategy made legible, the short-acting MDMA-analogue applications are the clearest available signal of where the money believes MDMA therapy is actually heading: shorter, owned, and engineered around the barrier the original molecule was never going to clear.